Evidence map›Paper›PMID 40857023›Full record

SynthesisHead & neck2025

Podoplanin Expression and the Risk of Malignant Transformation of Oral Pre-Malignant Disease: A Systematic Review and Meta-Analysis.

Erin E Briggs, Nathaniel Schlosser, Shaun A Nguyen, Evan Graboyes, Jason G Newman, Alexandra E Kejner, Greer Albergotti, Michael Bobian, Angela Yoon, Yuri Peterson and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Erin E BriggsDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID 0009-0003-2691-9074
Nathaniel SchlosserUS Army Maneuver Center of Excellence, Fort Moore, Georgia, USA.ORCID 0009-0007-3573-1777
Shaun A NguyenDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID 0000-0003-0664-4571
Evan GraboyesDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID 0000-0003-3766-468X
Jason G NewmanDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Alexandra E KejnerDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Greer AlbergottiDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Michael BobianDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Angela YoonDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Yuri PetersonDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Dauren AdilbayDepartment of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J Lemasters · 2009 to 2026
$42.7M
NCI NIH HHS P30 CA138313
6 · The paper itself

Abstract

backgroundPodoplanin is a mucin-like transmembrane glycoprotein expressed in oral epithelium with a documented role in cell motility, tumorigenesis, tumor invasion, and metastasis. Podoplanin is a potentially valuable biomarker for determining malignant transformation of oral premalignant disease (OPMD).

methodsA systematic search was done in accordance with PRISMA guidelines for articles reporting podoplanin expression in OPMD. The outcomes compared were the presence of podoplanin expression, the grade of podoplanin expression, and the incidence of malignant transformation. Statistical analysis of these outcomes included proportions (%), sensitivity, negative predictive value, and hazard ratio (HR) with 95% confidence intervals (CI).

resultsThere were 14 included studies (N = 971) with 78.7% OPMD, 13.9% OSCC, and 7.4% healthy controls. Positive expression of podoplanin had a sensitivity and negative predictive value for malignant transformation of 78.9% [95% CI: 69.7%-86.2%] and 88.8% [84.4%-92.1%], respectively. The hazard ratio was 4.4 for the malignant transformation of podoplanin expressing OPMDs [95% CI: 2.6-7.4].

conclusionsPodoplanin expression levels increased in a gradient from normal tissue to OPMD to OSCC, respectively. Furthermore, OPMD with podoplanin expression has higher rates of malignant transformation than OPMDs not expressing podoplanin.

Indexed as

Carcinoma, Squamous CellCell Transformation, NeoplasticMembrane GlycoproteinsMouth NeoplasmsPrecancerous ConditionsBiomarkers, TumorHumansPodoplaninRisk AssessmentBiomarkers, TumorMembrane GlycoproteinsPDPN protein, humanPodoplaninbiomarkermalignant transformationoral cavityoral pre‐malignant diseaserisk stratification

Identifiers

PMID40857023
PMCPMC12541684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.